These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12724470)

  • 1. Favorable effect of milnacipran on depression induced by interferon-alpha.
    Yoshida K; Higuchi H; Takahashi H; Shimizu T
    J Neuropsychiatry Clin Neurosci; 2003; 15(2):242-3. PubMed ID: 12724470
    [No Abstract]   [Full Text] [Related]  

  • 2. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports.
    Takahashi H; Kamata M; Yoshida K; Higuchi H; Shimizu T
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):351-3. PubMed ID: 15694247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of milnacipran, fluvoxamine and paroxetine for inhibited and agitated depression.
    Morishita S; Arita S
    Eur Psychiatry; 2004 Nov; 19(7):450-1. PubMed ID: 15504656
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury.
    Kanetani K; Kimura M; Endo S
    J Nippon Med Sch; 2003 Aug; 70(4):313-20. PubMed ID: 12928711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of severe antidepressant-induced nausea with a combination of milnacipran and olanzapine.
    Yoshida K; Higuchi H; Ozaki N
    Pharmacopsychiatry; 2007 Mar; 40(2):84-5. PubMed ID: 17447181
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of milnacipran on the depressive state in patients with Alzheimer's disease.
    Mizukami K; Tanaka Y; Asada T
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1342-6. PubMed ID: 16603301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raynaud's syndrome in a patient treated with milnacipran.
    Bourgade B; Jonville-Béra AP; Le Garé C; Ferquel D; Autret-Leca E
    Ann Pharmacother; 1999 Sep; 33(9):1009-10. PubMed ID: 10492510
    [No Abstract]   [Full Text] [Related]  

  • 8. Milnacipran for chronic pain in the orofacial region.
    Pae CU
    Clin Neuropharmacol; 2010; 33(5):270. PubMed ID: 20864840
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region.
    Ito M; Kimura H; Yoshida K; Kimura Y; Ozaki N; Kurita K
    Clin Neuropharmacol; 2010; 33(2):79-83. PubMed ID: 20375656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.
    Morishita S; Arita S
    Hum Psychopharmacol; 2004 Aug; 19(6):405-8. PubMed ID: 15303244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain.
    Obata H; Saito S; Koizuka S; Nishikawa K; Goto F
    Anesth Analg; 2005 May; 100(5):1406-1410. PubMed ID: 15845695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Milnacipran for the drastic improvement of refractory pain in a patient without depressive symptoms: a case report.
    Kito S; Nakajima T; Koga Y
    Eur Psychiatry; 2005 Jun; 20(4):355. PubMed ID: 16018932
    [No Abstract]   [Full Text] [Related]  

  • 13. Milnacipran in panic disorder with agoraphobia and major depressive disorder: a case report.
    Chen MH; Liou YJ
    Clin Neuropharmacol; 2011; 34(5):201-2. PubMed ID: 21926486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.
    Yoshida K; Higuchi H; Kamata M; Takahashi H; Inoue K; Suzuki T; Itoh K; Ozaki N
    J Psychopharmacol; 2007 Aug; 21(6):650-6. PubMed ID: 17092970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating depression with SNRIs: who will benefit most?
    Isaac MT
    CNS Spectr; 2008 Jul; 13(7 Suppl 11):15-21. PubMed ID: 18622370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Milnacipran and selective serotonin reuptake inhibitors in major depression.
    Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs.
    Rénéric JP; Bouvard M; Stinus L
    Behav Brain Res; 2002 Nov; 136(2):521-32. PubMed ID: 12429415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of selective serotonin reuptake inhibitor-induced sexual dysfunction without worsening of depressive symptom after switching to milnacipran.
    Takahashi H; Ishigooka J
    Clin Neuropharmacol; 2009; 32(3):177-8. PubMed ID: 19483494
    [No Abstract]   [Full Text] [Related]  

  • 19. Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor.
    Preskorn SH
    J Psychiatr Pract; 2004 Mar; 10(2):119-26. PubMed ID: 15330407
    [No Abstract]   [Full Text] [Related]  

  • 20. Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium.
    Bernstein CD; Albrecht KL; Marcus DA
    Expert Opin Pharmacother; 2013 May; 14(7):905-16. PubMed ID: 23506481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.